Skip to main content
Terug
PCVX logo

Vaxcyte, Inc.

Datakwaliteit: 100%
PCVX
NASDAQ Healthcare Biotechnology
€ 55,94
▲ € 1,22 (2,23%)
Marktkapitalisatie: 8,05B
Dagbereik
€ 55,05 € 57,12
52-Weeksbereik
€ 27,66 € 75,33
Volume
1.024.037
50D / 200D Gem.
€ 54,82 / € 42,62
Vorige Slotkoers
€ 54,72

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -10,5 0,4
P/B 3,0 2,9
ROE % -25,6 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 83,00 +48.4%
Low: € 77,00 High: € 89,00
Forward WPA
-€ 7,18
Omzet Sch.
25 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 6,17
€ 6,17 – € 6,17
2,3 B 2
FY2029 € 1,14
€ 1,14 – € 1,14
1,4 B 4
FY2028 -€ 5,95
-€ 9,82 – -€ 4,39
290 M 6

Belangrijkste Punten

Debt/Equity of 0,09 — conservative balance sheet
Negative free cash flow of -669,29M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-25,59%
ROIC-23,77%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,09
Current Ratio7,91
Interest Coverage0,00

Waardering

P/E Ratio
-10,50
P/B Ratio3,00
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -766,63M
ROE -25,59% ROA -25,17%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -669,29M
ROIC -23,77% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,09 Current Ratio 7,91
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -10,50 P/B Ratio 3,00
P/S Ratio N/A PEG Ratio -0,17
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 8,05B Enterprise Value 8,11B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -766,63M -463,93M -402,27M -223,49M -100,08M
EPS (Diluted) -5,63 -3,80 -4,14 -3,44 -1,93
Gross Profit 0,0 0,0 0,0 0,0 0,0
Operating Income -923,68M -569,55M -468,04M -232,26M -103,67M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3,05B 3,51B 1,41B 1,01B 324,34M
Total Liabilities 360,46M 205,50M 167,45M 52,57M 40,32M
Shareholders' Equity 2,69B 3,31B 1,24B 953,61M 284,02M
Total Debt 228,84M 71,11M 29,22M 17,94M 16,78M
Cash & Equivalents 173,96M 387,88M 397,45M 834,66M 68,99M
Current Assets 1,63B 1,79B 1,10B 942,56M 256,35M
Current Liabilities 205,75M 140,18M 145,34M 40,53M 28,72M